20/20 Biolabs Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AIDX research report →
Range $5 – $5
Price Chart
About the company
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test.
- CEO
- Jonathan Cohen
- IPO
- 2026
- Employees
- 14
- HQ
- Gaithersburg, MD, US
Get TickerSpark's AI analysis on AIDX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $4.64M
- P/E
- -0.50
- PEG
- 0.01
- P/S
- 2.28
- P/B
- 1.29
- EV/EBITDA
- -0.14
- Div Yield
- 0.00%
- Gross Margin
- 31.52%
- Op Margin
- -215.69%
- Net Margin
- -285.00%
- ROE
- -387.27%
- ROIC
- -116.89%
Latest fiscal year · YoY change
- Revenue
- $2.05M+16.7%
- Gross Profit
- $604.54K+67.8%
- Op Income
- $-3,330,871
- Net Income
- $-3,738,821+32.7%
- EPS
- $-0.60+48.3%
- OCF Growth
- -73769.9%
- FCF Growth
- -73770.0%
- 52W High
- $50.00
- 52W Low
- $0.33
- 50D MA
- $0.49
- 200D MA
- $1.46
- Beta
- 1.54
- RSI (14)
- 36
- Avg Volume
- 90.86K
No earnings-call transcripts are available for AIDX yet.
- Free Float
- 66.4%
- Shares Outstanding
- 12.25M
- Float Shares
- 8.13M
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Cresset Asset Management, LLC | 240.12K | ▼ 24.25K |
| Hrt Financial LP | 89.27K | ▲ 89.27K |
| Vanguard Fiduciary Trust Co | 52.09K | ▲ 52.09K |
| Geode Capital Management, LLC | 49.14K | ▲ 49.14K |
| Atlantic Union Bankshares Corp | 35.10K | ▲ 35.10K |
| Vanguard Capital Management LLC | 24.53K | ▲ 24.53K |
| Citadel Advisors LLC | 23.20K | ▲ 6.98K |
| Bank Of America Corp | 13.02K | ▲ 13.02K |
| Susquehanna International Group, Llp | 10.01K | ▲ 10.01K |
| Mcdonald Partners LLC | 2.80K | ▲ 2.80K |
| Signaturefd, LLC | 767 | ▲ 767 |
| Morgan Stanley | 283 | ▲ 283 |
Held by 6 ETFs
Biggest fund positions in AIDX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 2, 26 | Bergman Alan B. | other | 100,000 |
| Apr 2, 26 | Zhou Jiming | other | 150,000 |
| Mar 3, 26 | Cohen Jonathan M | other | 352,936 |
| Feb 19, 26 | Rollins John Woodson | other | 6,135 |
| Feb 19, 26 | Rollins John Woodson | other | 13,029 |
| Feb 19, 26 | Rollins John Woodson | other | 13,029 |
| Feb 19, 26 | Rollins John Woodson | other | 6,135 |
| Feb 19, 26 | Ross Michael A. | other | 31 |
| Feb 19, 26 | Ross Michael A. | other | 31 |
| Feb 19, 26 | Compton John G. | other | 7,669 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AIDX coverage
Recent articles, reports, and earnings notes.
No research on AIDX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AIDX report →20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
globenewswire.com · Oct 2
20/20 Biolabs Inc (NASDAQ:AIDX) Stock Short Interest Declines 50.4%
defenseworld.net · Oct 1
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
globenewswire.com · Sep 29
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
globenewswire.com · Aug 28
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
globenewswire.com · Aug 26
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
globenewswire.com · Aug 17
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour
globenewswire.com · Jul 30
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
globenewswire.com · Jul 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.